- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05355831
Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation (PRACTISE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately two thirds of stroke patients have reduced motor function which have a large impact on both activities of daily living and quality of life. Only 12-34% achieve full motor recovery.
There is a growing interest in using non-invasive brain stimulation (NIBS) techniques to supplement neurorehabilitation. NIBS can modulate cortical excitability and is a powerful tool for motor rehabilitation post-stroke. Application Transcranial Direct Current Stimulation (TDCS) is currently emerging as a tool used in neurorehabilitaiton. Prior studies have shown that TDCS-stimulation prior to physical training may significantly improve of motor function post-stroke. However, up to 50% of the participants recieving active TDCS show no response to stimulation.
A one-size-fits-all approach to TDCS in stroke rehabilitation may not be optimal and a more precise and individualized targeting is warranted to stimulate functionally relevant areas.
In this study TDCS will be personalized for stroke patients with upper-extremity paresis using individual functional and structural Magnetic Resonance Imaging (MRI) and an electric field modelling pipeline developed at Danish Research Centre for Magnetic Resonance (DRMCR). Based on these measures the electric current induced by TDCS will individually target the area with residual neural activity during movement. The effect of personalized TDCS will be assessed by clinical measures of motor improvement. Sub-studies furthermore assess if the functional reorganization of motor networks is affected by personalized TDCS by application of functional magnetic resonance (fMRI) and.
The study will have 3 phases:
- Personalization: The stimulation profile of each patient will be individualized using structural MRI a pipeline for simulation based on MRI (SimNIBS) to make individual anatomical head models in order to estimate the best montage and current dosage. Further, task-based fMRI will be used to estimate residual motor activity location. The target current is set in the area displaying the highest residual motor activity in sensorimotor areas.
- Intervention: Four weeks upper extremity training program of specialized supervised physiotherapeutic training 3 times per week. Each training session consists of 2x 20 minutes of training with concurrent personalized TDCS stimulation or montage of equipment but no stimulation (sham). Each bloc of 20 minutes training is separated by a small break of 5-10 minutes. Both patient, therapist and investigator will be blinded to the stimulation mode (activ TDCS or sham)
- Follow-up: Immediately after the 4 weeks of intervention and 12 weeks after intervention has ended, follow-up with clinical examination and brain MRI will be done.
Ad baseline Transcranial Magnetic Stimulation (TMS) will be done as well to assess corticospinal integrity as well as estimation of intracortical inhibition.
Hypothesis:
The main hypothesis is that personalized ipsi-lesional anodal TDCS during specialized individualized arm-training will lead to significantly greater improvements in upper-extremity motor function compared to sham.
Substudy with healthy controls:
A cohort of 20 healthy age- and sex matched controls will be recruited for one session of MRI and TMS identical to the procedure of the patients at baseline as well as the same questionnaires (Protocol amendment approved by the local Ethics Committee the 10th October 2022).
These data will be analyzed in a substudy for normative comparison between the stroke patients and healthy age- and sex-matched controls.
Hypothesis - Healthy Controls:
Stroke patients will exhibit a higher laterality index measured by fMRI and a stronger degree of interhemispheric inhibition at baseline compared to healthy controls measued by task-related fMRI and by TMS iSP and SICI.
The degree of interhemispheric inhibition in stroke patients will normalize during recovery and be similar to normal controls at the last follow-up after 12 weeks.
Further, the degree of normalization of the interhemispheric inhibition in stroke patients will be proportional to degree of improvement of the upper-extremity measured by UE-FMA.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Christina Krusse, MD, Prof
- Phone Number: +4538681233
- Email: christina.kruuse@regionh.dk
Study Contact Backup
- Name: Mia Kolmos, MD
- Phone Number: +4538681375
- Email: mia.kolmos@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2200
- Recruiting
- Copenhagen University Department of Nutrition and Exercise
-
Contact:
- Anke Karabanov, MSc, PhD
- Phone Number: +4535328039
- Email: anke@nexs.ku.dk
-
Sub-Investigator:
- Anke Karabanov, MSc, PhD
-
Herlev, Denmark, 2730
- Recruiting
- Department of Neurology, Herlev Gentofte Hospital
-
Contact:
- Mia Kolmos, MD
- Phone Number: +4538681375
- Email: mia.kolmos@regionh.dk
-
Contact:
- Christina Kruuse, MD, Prof
- Phone Number: +4538681233
-
Principal Investigator:
- Christina Kruuse, MD, Prof
-
Sub-Investigator:
- Mia Kolmos, MD
-
Hvidovre, Denmark, 2650
- Recruiting
- Danish Research Centre for Magnetic Resonance
-
Contact:
- Hartwig R Siebner, MD, Prof
- Phone Number: +4538626541
- Email: hartwig.roman.siebner@regionh.dk
-
Contact:
- Axel Thielscher, MSc, Prof
- Phone Number: +4538623326
- Email: axelt@drcmr.dk
-
Sub-Investigator:
- Hartwig R Siebner, MD, Prof
-
Sub-Investigator:
- Axel Thielscher, MSc, Prof
-
Sub-Investigator:
- Marie Louise Liu, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patients - Inclusion Criteria:
- Age >18 years
- Ischemic stroke confirmed by clinical and imaging criteria
- Hemiparesis including reduced upper-extremity function
- Location of stroke either cortically involving middle cerebral artery or the anterior cerebral artery circulation or subcortical (involving thalamus, basal ganglia).
- NIHSS score >2 and <8
- Modified Rankin Scale (mRS) ≤ 3
- Index of stroke within 4 weeks of inclusion
- Signed informed consent
Patients - Exclusion Criteria:
- >50% stenosis of extra- or intracranial artery as well as vascular malformations or aneurisms detected by brain CT-angiography.
- Exclusively ischemic stroke in spine, pons, brainstem, medulla or cerebellum.
- History of seizures, epilepsy, anxiety, dementia alcohol- or drug abuse.
- Prior serious head injury or neurosurgery
- Frequent severe headaches or migraine.
- Pregnancy or breastfeeding
- Current use of neuro-receptor/transmitter modulating medication, or medication interfering with seizure threshold (such as antiepileptic medication, some antidepressants, anxiety medication, antihistamines, stimulant drugs for attention deficit hyperactivity disorder).
- Pacemaker, implantable cardiac device unit (ICD-unit), metal fragments or other materials implanted not compatible with MRI (see appendix B).
- Claustrophobia
- Prior adverse effect to TDCS or Transcranial Magnetic Stimulation.
- Not able to provide informed consent.
- Terminally ill or short life expectancy.
Healthy controls - Inclusion criteria:
- Age between >18 years (matched to patients)
- Sex and age matched to patients
- Able bodied
- Have the ability to comply with all requirements of the study protocol, as determined by the investigator
- No history of stroke or dementia
- Eligible for MRI and TMS
Healthy controls - Exclusion Criteria:
- History of neurologic disease
- History of cerebral haemorrhage or brain damage
- Pregnancy
- Pacemaker or other implanted electronic devices
- Claustrophobia
- Psychiatric disorder
- Epilepsy or close relatives suffering from epilepsy
- Migraine
- Any contraindication to MRI or TMS
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Transcranial Direct Current Stimulation
Anodal TDCS 1mV for 2x 20 minutes.
|
See arm/group description
|
Sham Comparator: Sham stimulation
2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down).
|
See arm/group description
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper-extremity motor outcome
Time Frame: From baseline to four months
|
Difference in change in Upper-extremity Fugl-Meyer Assessment (UE-FMA) score.
Range 0-66.
|
From baseline to four months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper-extremity function
Time Frame: From baseline to four months
|
Difference in change in Action Reach Arm Test (ARAT) score.
Range 0-57.
High scores mean a better outcome.
|
From baseline to four months
|
Stroke severity
Time Frame: From baseline to four months
|
Difference in change in National Health Institutes Stroke Scale (NIHSS).
Range 0-42.
High scores mean a better outcome.
|
From baseline to four months
|
Stroke disability
Time Frame: From baseline to four months
|
Difference in change in Modified Rankin Scale (mRS).
Range 0-6.
Lower scores mean a better outcome.
|
From baseline to four months
|
ADL performance
Time Frame: From baseline to four months
|
Difference in change in Bartel's 20-item Index (BI-20).
Range 0-100.
Higher scores mean better outcome.
|
From baseline to four months
|
Gait speed
Time Frame: From baseline to four months
|
Difference in change in 10 Meter Walk Test (10MWT) in minutes:sec.
|
From baseline to four months
|
Physical Activity
Time Frame: From baseline to four months
|
Difference in change in Physical Activity Scale 2.0 (PAS2).
The answers will be translated into a Metabolic Equivalent of Task (MET)-score.
The higher MET-score the higher level of activity.
|
From baseline to four months
|
Montreal Cognitive Assessment
Time Frame: From baseline to four months
|
Difference in change in Montreal Cognitive Assessment (MoCA) score.
Score range 0-30.
Higher scores mean a better outcome.
|
From baseline to four months
|
Symbol Digit Modalities Test
Time Frame: From baseline to four months
|
Difference in change in Symbol Digit Modalities Test (SDMT) score.
Score range 0-110.
Higher scores mean a better outcome.
|
From baseline to four months
|
Health-related quality of life
Time Frame: From baseline to four months
|
Difference in change in EQ-5D-5L score.
Range 1 to 20, a high score means low health-related quality of life.
Includes a 0-100 visual analogue scale for overall percieved quality of life.
|
From baseline to four months
|
Becks Depression Inventory (BDI)
Time Frame: From baseline to four months
|
Difference in change in BDI-II score.
Score range 0-63.
Higher score means increased risk of depression.
|
From baseline to four months
|
Fatigue Severity Scale (FSS)
Time Frame: From baseline to four months
|
Difference in change in FSS score.
Score range 0-7.
Higher score means increased fatigue severity.
|
From baseline to four months
|
WHO-5 Well-Beeing Index
Time Frame: From baseline to four months
|
Difference in change in WHO-5 score.
Score range 0-100.
Higher score means better quality of life.
|
From baseline to four months
|
Biomarker of inflammation and exercise
Time Frame: From baseline to four months
|
Difference in change in serum level Cathepsin-B (unit mikro gram/L)
|
From baseline to four months
|
MRI - Cerebral bloodflow
Time Frame: From baseline to four months
|
Change in cerebral blood flow measured with arterial spin labeling (ASL) during rest
|
From baseline to four months
|
fMRI - Effective connectivity
Time Frame: From baseline to four months
|
Change in activation patterns measured with blood-oxygen-level dependent (BOLD) during both single and bimanual task.
|
From baseline to four months
|
fMRI - Interhemispheric inhibition
Time Frame: From baseline to four months
|
Change in activation pattern measured by blood-oxygen-level dependent (BOLD) during both single and bimanual task.
|
From baseline to four months
|
fMRI - Laterality Index
Time Frame: From baseline to four months
|
Change in activation pattern for hemispheric dominance measured by the ratio of active fMRI voxels in each hemisphere.
|
From baseline to four months
|
MRI - Corticospinal integrity
Time Frame: From baseline to four months
|
Change in corticospinal integrity measured by diffusion MRI.
|
From baseline to four months
|
MRI - Infarct lesion load
Time Frame: From baseline to four months
|
Difference in change in size of infarct lesion meaured by structural MRI.
|
From baseline to four months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain Derived Neutrotrophic Factor (BDNF) genetic polymorphism
Time Frame: Baseline
|
Determination of BDNF genetic variant - either Val66Met variant or wildtype.
|
Baseline
|
Feasibility of intervention
Time Frame: From baseline to four months
|
Completion of intervention in the active vs. control group
|
From baseline to four months
|
TMS - motor evoked potential
Time Frame: Baseline
|
Determination of existence of a MEP-response by TMS as an indicator of cortico-spinal tract integrity.
Prognostic marker of motor recovery.
|
Baseline
|
TMS - Ipsilateral silent period (iSP)
Time Frame: Baseline
|
Determination of degree of interhemispheric inhibition unaffected vs. affected hemisphere
|
Baseline
|
TMS - Short latency intracortical inhibition (SICI)
Time Frame: Baseline
|
Determination of degree of interhemispheric inhibition unaffected vs. affected hemisphere
|
Baseline
|
TMS - cortico-motor conduction time (CMCT)
Time Frame: Baseline
|
Determination of conduction time from stimulation of cortical neurons to response measured in a peripheral muscle (FDI)
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christina Kruuse, MD, Prof, Herlev Gentofte Hospital, Department of Neurology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-20036199
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Active Transcranial Direct Current Stimulation
-
Louisiana State University and A&M CollegeNot yet recruitingParkinson Disease
-
Holland Bloorview Kids Rehabilitation HospitalRecruitingStroke | Traumatic Brain Injury | Acquired Brain Injury | HemiparesisCanada
-
University of LiegeResearch Center of Neurology, Russia; Fondazione Salvatore Maugeri, Italy; Université... and other collaboratorsCompletedDisorder of ConsciousnessBelgium
-
Universidad Francisco de VitoriaUniversidad Nacional de Educación a Distancia; Hospital Beata María AnaNot yet recruitingCerebral Palsy | Paediatric Stroke | Paediatric Brain Damage | Paediatric Traumatic Brain Injury | Paediatric Acquired Brain InjurySpain
-
Taipei Veterans General Hospital, TaiwanRecruiting
-
Universidad Francisco de VitoriaUniversidad Rey Juan Carlos; Hospital Beata María AnaCompletedPain | Parkinson DiseaseSpain
-
Federal University of São PauloUniversity of Pittsburgh; Universidade Federal do AmapáCompleted
-
D'Or Institute for Research and EducationCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
Centre Hospitalier St AnneNot yet recruiting
-
Manhattan Psychiatric CenterCompletedSchizophrenia | Auditory HallucinationUnited States